A 12-week, Randomized, Double-masked, Parallel Group Comparison of Evening Dosing With Xalacom in Subjects With Glaucoma

Completed · Phase 3

Conditions studied: Open Angle Glaucoma, Ocular Hypertension

In brief

To demonstrate statistical superiority of the combination of latanoprost and timolol to the individual therapy of latanoprost and timolol based on intraocular pressure measurements at 8 AM, 10 AM, 4 PM at weeks 2, 6 and 12.

Key facts

Study ID

NCT00277498

Run by

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

People needed

528

Starts

2005-12-01

Expected to finish

2007-06-01

Last updated by the study team

2021-02-18

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Uni- or bilateral diagnosis of primary open angle glaucoma or ocular hypertension on beta-blocker monotherapy or dual therapy in which at least one medication is a beta-blocker for at least 4 weeks prior to screening

You may not qualify if…

• Closed/ barely open anterior chamber angle or history of acute angle closure glaucoma.
• History of ALT (Argon Laser Trabeculoplasty) or SLT(selective Laser) within 3 months prior to screening

Where it is running

• Pfizer Investigational Site — Flagstaff, Arizona, United States
• Pfizer Investigational Site — Artesia, California, United States
• Pfizer Investigational Site — Los Angeles, California, United States
• Pfizer Investigational Site — Newport Beach, California, United States
• Pfizer Investigational Site — Sacramento, California, United States
• Pfizer Investigational Site — San Francisco, California, United States
• Pfizer Investigational Site — Colorado Springs, Colorado, United States
• Pfizer Investigational Site — Gainesville, Florida, United States
• Pfizer Investigational Site — Lecanto, Florida, United States
• Pfizer Investigational Site — Miami, Florida, United States
• Pfizer Investigational Site — Panama City, Florida, United States
• Pfizer Investigational Site — Idaho Falls, Idaho, United States
• Pfizer Investigational Site — Bourbonnais, Illinois, United States
• Pfizer Investigational Site — Calumet City, Illinois, United States
• Pfizer Investigational Site — Chicago, Illinois, United States
• Pfizer Investigational Site — Chicago, Illinois, United States
• Pfizer Investigational Site — Evansville, Indiana, United States
• Pfizer Investigational Site — Madison, Indiana, United States
• Pfizer Investigational Site — New Albany, Indiana, United States
• Pfizer Investigational Site — Newburgh, Indiana, United States
• Pfizer Investigational Site — Iowa City, Iowa, United States
• Pfizer Investigational Site — Wichita, Kansas, United States
• Pfizer Investigational Site — Louisville, Kentucky, United States
• Pfizer Investigational Site — Bangor, Maine, United States
• Pfizer Investigational Site — Birmingham, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.